South Dakota law lists an FDA-approved drug product containing crystalline psilocybin in Schedule IV, while excluding it from the Schedule I psilocybin listing.
South Dakota law lists an FDA-approved drug product containing crystalline psilocybin in Schedule IV and excludes that product from the Schedule I psilocybin listing.
South Dakota law lists the product in Schedule IV. This applies to the pharmaceutical composition of crystalline polymorph psilocybin in an FDA-approved drug product. The product must be an FDA-approved drug product containing the pharmaceutical composition of crystalline polymorph psilocybin.
No hearings or votes scheduled.